Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2014 1
2015 3
2016 2
2017 1
2018 4
2019 3
2020 2
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, Diggelmann S, Challier J, Mössner E, Hosse RJ, Hofer T, Brünker P, Joseph C, Benz J, Ringler P, Stahlberg H, Lauer M, Perro M, Chen S, Küttel C, Bhavani Mohan PL, Nicolini V, Birk MC, Ongaro A, Prince C, Gianotti R, Dugan G, Whitlow CT, Solingapuram Sai KK, Caudell DL, Burgos-Rodriguez AG, Cline JM, Hettich M, Ceppi M, Giusti AM, Crameri F, Driessen W, Morcos PN, Freimoser-Grundschober A, Levitsky V, Amann M, Grau-Richards S, von Hirschheydt T, Tournaviti S, Mølhøj M, Fauti T, Heinzelmann-Schwarz V, Teichgräber V, Colombetti S, Bacac M, Zippelius A, Klein C, Umaña P. Claus C, et al. Among authors: freimoser grundschober a. Sci Transl Med. 2019 Jun 12;11(496):eaav5989. doi: 10.1126/scitranslmed.aav5989. Sci Transl Med. 2019. PMID: 31189721 Free PMC article.
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P. Bacac M, et al. Among authors: freimoser grundschober a. Clin Cancer Res. 2018 Oct 1;24(19):4785-4797. doi: 10.1158/1078-0432.CCR-18-0455. Epub 2018 May 1. Clin Cancer Res. 2018. PMID: 29716920 Free article.
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P. Klein C, et al. Among authors: freimoser grundschober a. Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017. Oncoimmunology. 2017. PMID: 28405498 Free PMC article.
A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Peterson LB, Bell CJM, Howlett SK, Pekalski ML, Brady K, Hinton H, Sauter D, Todd JA, Umana P, Ast O, Waldhauer I, Freimoser-Grundschober A, Moessner E, Klein C, Hosse RJ, Wicker LS. Peterson LB, et al. Among authors: freimoser grundschober a. J Autoimmun. 2018 Dec;95:1-14. doi: 10.1016/j.jaut.2018.10.017. Epub 2018 Nov 13. J Autoimmun. 2018. PMID: 30446251 Free PMC article.
p95HER2-T cell bispecific antibody for breast cancer treatment.
Rius Ruiz I, Vicario R, Morancho B, Morales CB, Arenas EJ, Herter S, Freimoser-Grundschober A, Somandin J, Sam J, Ast O, Barriocanal ÁM, Luque A, Escorihuela M, Varela I, Cuartas I, Nuciforo P, Fasani R, Peg V, Rubio I, Cortés J, Serra V, Escriva-de-Romani S, Sperinde J, Chenna A, Huang W, Winslow J, Albanell J, Seoane J, Scaltriti M, Baselga J, Tabernero J, Umana P, Bacac M, Saura C, Klein C, Arribas J. Rius Ruiz I, et al. Among authors: freimoser grundschober a. Sci Transl Med. 2018 Oct 3;10(461):eaat1445. doi: 10.1126/scitranslmed.aat1445. Sci Transl Med. 2018. PMID: 30282693 Free PMC article.
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
Geiger M, Stubenrauch KG, Sam J, Richter WF, Jordan G, Eckmann J, Hage C, Nicolini V, Freimoser-Grundschober A, Ritter M, Lauer ME, Stahlberg H, Ringler P, Patel J, Sullivan E, Grau-Richards S, Endres S, Kobold S, Umaña P, Brünker P, Klein C. Geiger M, et al. Among authors: freimoser grundschober a. Nat Commun. 2020 Jun 24;11(1):3196. doi: 10.1038/s41467-020-16838-w. Nat Commun. 2020. PMID: 32581215 Free PMC article.
Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study.
Hartimath SV, Manuelli V, Zijlma R, Signore A, Nayak TK, Freimoser-Grundschober A, Klein C, Dierckx RAJO, de Vries EFJ. Hartimath SV, et al. Among authors: freimoser grundschober a. Oncotarget. 2018 Jan 2;9(6):7162-7174. doi: 10.18632/oncotarget.23852. eCollection 2018 Jan 23. Oncotarget. 2018. PMID: 29467958 Free PMC article.
Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.
Bell CJ, Sun Y, Nowak UM, Clark J, Howlett S, Pekalski ML, Yang X, Ast O, Waldhauer I, Freimoser-Grundschober A, Moessner E, Umana P, Klein C, Hosse RJ, Wicker LS, Peterson LB. Bell CJ, et al. Among authors: freimoser grundschober a. J Autoimmun. 2015 Jan;56:66-80. doi: 10.1016/j.jaut.2014.10.002. Epub 2014 Oct 30. J Autoimmun. 2015. PMID: 25457307 Free PMC article.
16 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page